Lenz Therapeutics, Inc. · NASDAQ:LENZ
Lenz Therapeutics — Investor Presentation (September 2023)
24 slides from Lenz Therapeutics's investor presentation, September 2023
Slide 1: LENZ Therapeutics September 2023
LENZ THERA PEUT I September 2023
Slide 2: LENZ Therapeutics – positioned for leadership in $3B+ market
LENZ THERAPEUTICS – positioned for leadership in $3B+ market Late stage exclusive aceclidine-based eye drop with potential of providing all day seamless vision for the vast majority of presbyopes Unique MOA Only miotic shown to achieve pupil sweet spot <2mm w/o myopic shift Profile Best-in-class 73%
Slide 3: Presbyopia, the inevitable loss of near vision
Problem Presbyopia, the inevitable loss of near vision Research shows adults over 45 lose on average 1.5 lines of near vision per 6 years1 Impacts Every year 120M 1.4M People in the US New Presbyopes2,3 Impacts over Potential $3B+ Market 120M People in the US 3
Slide 4: A non-invasive, reversible eye drop to treat presbyopia
Solution A non-invasive, reversible, eye drop to treat presbyopia that improves near vision while preserving distance vision Welcomed by all age groups Adapting Early Busy Active Presbyopes Midlife Aging 45 – 54 55 - 64 65+ An extension of youth, I’m not A return to younger times Deep acceptance of
Slide 5: How the eye focuses light for near and far vision
How the eye focuses light for near and far vision Distance vision: Near vision: The lens is in its native shape which The lens changes shape, known as enables far vision accommodation, to allow focus on close objects Contracted Relaxed ciliary muscles ciliary muscles Thick lens Thin lens 5
Slide 6: Presbyopia is the age-related loss of near vision
Presbyopia is the age-related loss of near vision Problem: Good The lens hardens with age, limiting accommodation and shifting near vision Before Presbyopia focus Visual Acuity Presbyopia Contracted ciliary muscles Poor Insufficient accommodation Distance Near For illustrative purposes only 6
Slide 7: Ideal eye drop creates a pinhole pupil while avoiding a myopic shift
Ideal eye drop creates a pinhole pupil while avoiding a myopic shift Create a pinhole pupil While avoiding a myopic shift FDA requires 3 lines of near vision improvement while not losing more than 1 line of distance vision 7
Slide 8: Reducing pupil diameter below 2mm increases depth-of-focus and near vision
Research shows reducing the pupil diameter below 2mm dramatically increases depth-of-focus and near vision 7,8 Total Depth-of-Focus Near Vision Improvement Total Depth-of-Focus (D) 6 0.6 Lighting Conditions (cd/m2) Lines Improvement 20 (Dark) 5 0.5 200 (Office) 4 2000 (Cloudy Day) 0.4 Average 3 0.3
Slide 9: Aceclidine is the only pupil selective miotic
Aceclidine is the only pupil selective miotic6 Iris sphincter muscle Ciliary muscle Independence ratio EC50 (nmol/l) EC50 (nmol/l) iris to ciliary EC50 25,000 Longitudinal 28 Aceclidine 900 20,000 Circular 22 1,800 3,360 Longitudinal 1.9 Pilocarpine 2,840 Circular 1.6 Carbachol 106 574 Longitudinal
Slide 10: Uniquely achieving <2mm pupil without myopic shift
Uniquely achieving <2mm pupil without myopic shift4 Miotic pinhole effect achieved Corresponding myopic shift (iris sphincter muscle) (ciliary muscle) -0.17 Diopters myopia 2% Aceclidine 1.40 mm 0.078 mm lens shift 0.07 mm increase lens thickness -1.3 Diopters myopia 2% Pilocarpine 1.35 mm 0.234 mm
Slide 11: One diopter of myopic shift is meaningful
One diopter of myopic shift is meaningful 20/20 20/50 Perfect vision 1 Diopter myopic shift 20/40 20/40 Drivers test line 11
Slide 12: Addressable market is largest when pinhole effect is decoupled from myopic shift
Addressable market is largest when pinhole effect is decoupled from myopic shift Adapting Early Busy Midlife Active Aging Presbyopia market segments 40 – 54 yrs 55 – 64 yrs Over 65 yrs 31% 30% 39% Target Market Aceclidine 100% All Eyes / All Day Other <20% Early Presbyopes / Emmetropes miotics 12
Slide 13: Best-in-class potential
Aceclidine Preservative free eye drop The first and only pupil selective miotic with potential to provide all eyes, all day near vision improvement Best-in-class potential 13
Slide 14: INSIGHT trial compared LNZ100 and LNZ101 against vehicle
INSIGHT trial compared LNZ100 and LNZ101 against vehicle on key variables LNZ100 Study Design • Multicenter safety and effectiveness study 1.75% Aceclidine • 5 US Sites, 50+ Patients • Double-masked, randomized, crossover - Ready to use • Placebo controlled - Preservative Free Eye Drop • 10 hr durat
Slide 15: Pupil diameter within the sweet spot for hours
Pupil diameter within the sweet spot for 10 hours Pupil Size Near Vision Improvement Biomarker LNZ100 (n=49) LNZ101 (n=50) Placebo (n=51) 4.0 3.5 Average pupil size reduced to ~1.6mm at 30 minutes Pupil size (mm) 3.0 Pupil size correlates to lines of near vision 2.5 improvement 2.03 2.0 2.0 Average
Slide 16: Primary 1 hour endpoint met and 10 hours duration
Primary 1 hour endpoint met and 10 hours duration ≥3-Line % Improvement Over Time (No loss of 5 or more letters distance) LNZ100 (n=49) LNZ101 (n=50) Placebo (n=51) 73 73 Extended category leadership with best- 71 69 in-class data for efficacy and duration for 62 64 both LNZ100 and LNZ101 56 57 58 5
Slide 17: Secondary 1 hour endpoint met and 10 hours duration
Secondary 1 hour endpoint met and 10 hours duration ≥2-Line % Improvement Over Time (No loss of 5 or more letters distance) LNZ100 (n=49) LNZ101 (n=50) Placebo (n=51) 92 92 86 86 82 78 78 78 Both LNZ100 and LNZ101 provided 74 72 69 74 69 clinically meaningful 2 lines or more NV 68 improvement for al
Slide 18: No impact to distance vision in normal and low light
No impact to distance vision in normal and low light Distance Visual Acuity Best Corrected LNZ100 (n=49) LNZ101 (n=50) Placebo (n=51) 20/15 No impact to distance vision in BETTER DISTANCE VISION normal light No impact to distance vision in low light Well tolerated, No drug related serious adverse ev
Slide 19: Broad exclusivity and patent protection layers
Broad exclusivity and patent protection layers FDA Granted Patents Under Exclusivity Patents Review 5 year 18 10 US NCE (Exp. 2034 - 2039) (beyond 2039) Ex-US N/A 19 61 Patents include both method of use and formulation patents 19
Slide 20: European historical use of 400M doses confirms expected low side effect profile
European historical use of 400M doses confirms expected low side effect profile Long history of use for Glaucoma • Approved for Glaucoma in Europe in 1970’s5 • Approved at higher concentration and QID dosing5 • Marketed in 12 European countries and 400M doses • Rapid anterior chamber penetration5 •
Slide 21: Management and Board
Management and Board Management: Eef Schimmelpennink Shawn Olsson Marc Odrich, MD Marv Garrett Gerald Horn, MD Melissa Rosness President and CEO Chief Commercial Officer Chief Medical Officer Sr. VP, Regulatory Senior Scientific Advisor & VP, CMC & Manufacturing & Quality Founder Board: Eef Schimmel
Slide 22: Medical Advisors
Medical Advisors Ophthalmology: Steven Dell, MD Deepinder Dhaliwal, MD John Doane, MD Kathryn Hatch, MD Terry Kim, MD Colman Kraff, MD Robert Osher, MD Medical Director UPMC Eye Center Discover Vision Centers Mass. Eye and Ear. Asst. Prof. Prof. of Ophthalmology Kraff Eye Institute Cincinnati Eye In
Slide 23: LNZ100 & LNZ101 positioned to be best-in-class presbyopia eye drop
LNZ100 & LNZ101 positioned to be best-in-class presbyopia eye drop Only miotic shown to achieve pupil diameter <2mm for Unique true depth of field expansion without overstimulating MOA Profile the ciliary muscle Aceclidine Highest placebo adjusted responder rates, suggesting a Best-in-class Propriet
Slide 24: References
References 1. Progression of Near Vision Loss and Incidence of Near Vision Impairment in an Adult Chinese Population, Han, Xiaotong, et al, Ophthalmology, 124(5): page 734, May 2017 2. Global Prevalence of Presbyopia and Vision Impairment from Uncorrected Presbyopia, Fricke, Timothy, et al, American
LENZ Therapeutics — Investor Presentation (September 2023) on 6ix